TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, ...

No explicit numerical revenue or EPS guidance was provided for 2026, but the company reaffirmed its focus on expanding the installed base and driving utilization, aiming for "approximately 120" ...

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative ...

Shares of Profound Medical tumbled after the company logged a wider fourth-quarter loss and revenue that missed Wall Street's expectations. The stock fell 19% to $6.09 in Friday trading. The shares ...

An update from Profound Medical ( (TSE:PRN) ) is now available.

Profound Medical Corp (PROF) reports a 43% revenue increase and global expansion, while addressing operational challenges and aiming for cash flow positivity.

King Faisal Specialist Hospital and Research Centre (KFSH) in Riyadh has successfully introduced a pioneering high-intensity focused ultrasound (HIFU) treatment for prostate cancer for the first time ...